Videos & Webinars
I-SPY 2 Trial Press Conference, September 12, 2018
The I-SPY 2 Trial Leadership team, including Berry Consultants' Don Berry, hosted a press conference to update the media, patients, and the public on the progress of an innovative adaptive platform clinical trial that is changing the outcomes of early stage, high-risk breast cancer and advancing precision medicine.
Introducing Decision-Making Under Uncertainty to Medical Research: Designing More Efficient and More Accurate Clinical Trials. Don Berry's presentation at the Simons Institute for the Theory of Computing at University of California Berkeley.
Berry Consultants released a new video series on adaptive designs during 2015-2016. The complete video library can be found on Berry Consultants You Tube Channel. Here are some of the videos released:
–Top Ten Misconceptions About Adaptive Trials (Berry Consultants Team)
–What Clinicians Should Know About Adaptive Clinical Trials (Dr. Roger Lewis)
–How to Design an Adaptive Trial – Lessons Learned So Far (Dr. Scott Berry)
–The Adaptive Platform Trial – The Statistical Efficiencies (Dr. Scott Berry)
–I-Spy 2 and Other Platform Trials (Dr. Don Berry)
–The Use of Historical Information in Clinical Trials (Dr. Kert Viele)
–Driving With Your Eyes Open (Dr. Jason Connor)
–In Silico Cinical Trial Design (Dr. Scott Berry)
–DSMBs for Adaptive Trials (Dr. Roger Lewis)
–The Value of Biomarkers (Dr. Jason Connor)
–NCAA Football and the Ebola Pandemic (Dr. Scott Berry)
-Multiplicities, Big Data = Big Problems, Irreproducible Research, & The Umbrella Man (Dr. Don Berry)
-The Billion Dollar Statistical Concept (Dr. Scott Berry)
-RE-ADAPT: Do Bayesian Adaptive Trials Offer Advantages for Comparative Effectiveness Research?
(Dr. Jason Connor)
-Rare Diseases and Slow Decline: Can Thomas Bayes Help? (Dr. Scott Berry)
The Lowdown on Adaptive Clinical Trials with Don Berry
Mendelspod.com interviews Don Berry through a podcast sponsored by the National Biomarker Development Alliance (NBDA) on July 28, 2014 that discusses a promising new approach to clinical trials.
President's Council of Advisors on Science and Technology (PCAST)
Don Berry presents as part of a panel of Researchers on the topic of "Improving Scientific Reproducibility in an Age of International Competition and Big Data I" at the PCAST Public Meeting on January 31, 2014.
The Design of Complex Adaptive Trials,
Scott Berry presents at the "Transforming Drug Development – Delivering Innovation and Efficiency through Adaptive Clinical Trials" conference that was co-sponsored by Berry Consultants.
A Fully Bayesian World: What a Wonderful World,
Scott Berry presents at the Royal Statistical Society's, "PSI Debate: This house believes that pharmaceutical drug development and regulation should become fully Bayesian".
Slowly but surely, Bayesian Ideas revolutionalize medical research,
Don Berry at the 2012 International Society for Bayesian Analysis (ISBA) World Meeting in Kyoto, Japan
The Biomarkers Consortium: I-SPY 2 Press Conference,
Don Berry speaks as part of the press conference for I-SPY 2, an innovative breast cancer clinical trial.
Adaptive Design for Clinical Trials,
Don Berry, speaking from AACR 2010 (American Association for Cancer Research), describes adaptive design for clinical trials.